Mushonga wechirwere cheshuga unogona kuvandudza zviratidzo zvechirwere cheParkinson
Lixisenatide, glucagon-like peptide-1 receptor agonist (GLP-1RA) yekurapa chirwere cheshuga, inononoka dyskinesia kune varwere vane chirwere chekutanga cheParkinson, maererano nemigumisiro yechikamu chechipiri chekuongorora kwekliniki yakabudiswa muNew England Journal of Medicine ( NEJM) musi wa4 Kubvumbi 2024.
Chidzidzo ichi, chinotungamirwa neUniversity Hospital yeToulouse (France), chakatora zvidzidzo zve156, zvakakamurwa zvakaenzana pakati peboka rekurapa lixisenatide neboka re placebo.Vatsvakurudzi vakayera kushanda kwemushonga vachishandisa Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPRSS) Chikamu chechitatu chechikamu, ine zvibodzwa zvepamusoro pachiyero zvichiratidza kukanganisa kwakanyanya kwekufamba.Zvigumisiro zvakaratidza kuti pamwedzi we12, chikamu cheMDS-UPDRS chikamu chechitatu chakaderera ne 0.04 points (inoratidza kuvandudzwa kuduku) muboka re lixisenatide uye yakawedzera ne 3.04 points (inoratidza kuwedzera kwechirwere) muboka re placebo.
Imwe yemazuva ano NEJM mupepeti yakataura kuti, pamusoro, idzi data dzinoratidza kuti lixisenatide yakadzivirira zvachose kuwedzera kwechirwere cheParkinson mukati memwedzi gumi nemiviri, asi izvi zvinogona kunge zviri maonero ane tariro.Yese yeMDS-UPDRS zviyero, kusanganisira Chikamu III, zviyero zvakaumbwa zvine zvikamu zvakawanda, uye kuvandudzwa mune chimwe chikamu kunogona kurwisa kuderera mune imwe.Mukuwedzera, mapoka maviri ekuedzwa anogona kunge akabatsirwa nekungotora chikamu mukuedza kwekliniki.Nekudaro, mutsauko uripo pakati pemapoka maviri ekuyedzwa unoratidzika sewechokwadi, uye mhedzisiro inotsigira mhedzisiro yelixisenatide pazviratidzo zvechirwere cheParkinson uye chirwere chinogona kuitika.
Panyaya yekuchengeteka, 46 muzana yezvidzidzo zvakarapwa ne lixisenatide vakanzwa kusvotwa uye 13 muzana vane ruzivo rwekurutsira.Nhepfenyuro yeNEJM inoratidza kuti chiitiko chemigumisiro inogona kukanganisa kushandiswa kwakapararira kwe lixisenatide mukurapa chirwere cheParkinson, uye naizvozvo kuwedzera kuongorora kuderedza dose uye dzimwe nzira dzokuyamura zvingave zvakakosha.
"Mukuedzwa uku, kusiyana kwezvikwata zve MDS-UPDRS zvaive zvakakosha asi zvishoma mushure memwedzi ye12 yekurapa ne lixisenatide. Kukosha kwekutsvaga uku hakusi muhukuru hwekuchinja, asi mune izvo zvinoratidzira."Mupepeti wambotaurwa anonyora kuti, "Chinonyanya kunetseka kuvarwere vakawanda veParkinson haisi mamiriro avo ezvinhu iye zvino, asi kutya kwekuwedzera kwechirwere. Kana lixisenatide inovandudza MDS-UPDRS zvibodzwa nepamusoro pe 3 points, ipapo kukosha kwekurapa kwemushonga kunogona kuderedzwa. Ukuwo, kana kushanda kwe lixisenatide kuchiwedzera, zvichiwedzera zvibodzwa neimwe 3 mapoinzi pagore mukati memakore mashanu kusvika gumi kana kupfuura, zvino izvi zvinogona kuve shanduko yechokwadi nhanho inotevera ndeyekuita miedzo yenguva refu."
Yakagadzirwa neFrench drugmaker Sanofi (SNY.US), lixisenatide yakabvumidzwa neUS Food and Drug Administration (FDA) yekurapa chirwere cheshuga cherudzi rwechipiri muna 2016, zvichiita kuti ive yechishanu GLP-1RA kutengeswa pasi rose. kubva kumakiriniki ekuedzwa, haisi iyo inoshanda mukudzikisa glucose sevamwe vayo liraglutide uye Exendin-4, uye kupinda kwayo mumusika weUnited States kwakauya gare gare kupfuura yavo, zvichiita kuti zvive zvakaoma kuti chigadzirwa chiwane nzvimbo.Muna 2023, lixisenatide yakabviswa pamusika weUS.Sanofi anotsanangura kuti izvi zvakakonzerwa nezvikonzero zvekutengesa kwete zvekuchengetedza kana nyaya dzekushanda nemushonga.
Chirwere cheParkinson chirwere cheneurodegenerative chinowanzoitika muzera repakati nepakati uye vakuru, zvakanyanya kuratidzwa nekuzorora kwekudedera, kusimba uye kunonoka kufamba, paine chikonzero chisingazivikanwe.Parizvino, tsigiro yekurapa kwechirwere cheParkinson ndeye dopaminergic replacement therapy, iyo inonyanya kushanda kuvandudza zviratidzo uye haina humbowo hunogutsa hwekukanganisa kufambira mberi kwechirwere.
Zviverengero zvakapfuura zvidzidzo zvakaona kuti GLP-1 receptor agonists inoderedza kuzvimba kwehuropi.Neuroinflammation inotungamira mukurasikirwa kunofambira mberi kwemasero europi anogadzira dopamine, chinhu chakakosha chechirwere cheParkinson.Nekudaro, chete GLP-1 receptor agonist vane mukana wehuropi vanobudirira muchirwere cheParkinson, uye nguva pfupi yadarika semaglutide uye liraglutide, izvo zvinonyatsozivikanwa nekuda kwekuremerwa kwavo uremu, hazvina kuratidza kugona kurapa chirwere cheParkinson.
Kare, kuyedza kwakaitwa nechikwata chevaongorori veInstitute of Neurology paYunivhesiti yeLondon (UK) yakawana kuti exenatide, iyo yakafanana ne lixisenatide, yakavandudza zviratidzo zvechirwere cheParkinson.Migumisiro yekuedza yakaratidza kuti pamasvondo e60, varwere vanobatwa neexenatide vaiva ne-1-point kuderedzwa muzvikoro zvavo zveMDS-UPDRS, asi avo vakarapwa ne placebo vaiva ne 2.1-point improvement.Yakagadzirwa naEli Lilly (LLY.US), kambani hombe yemishonga yeUS, exenatide ndiyo yekutanga pasi rose GLP-1 receptor agonist, yaive yatonga musika kwemakore mashanu.
Zvinoenderana nenhamba, vanosvika vatanhatu veGLP-1 receptor agonist vanga kana parizvino vari kuongororwa kushanda kwavo mukurapa chirwere cheParkinson.
Sekureva kweWorld Parkinson's Association, pari zvino kune varwere vane chirwere cheParkinson vanosvika miriyoni 5.7 pasi rose, uye vanosvika mamirioni mazana maviri nenomwe kuChina.Pakazosvika gore ra2030, China inenge yave nehafu yehuwandu hwePasinson pasi rose.Musika wepasi rose weParkinson's disease drug market uchave nekutengesa kweRMB 38.2 bhiriyoni muna 2023 uye inotarisirwa kusvika RMB 61.24 bhiriyoni muna 2030, maererano neDIResaerch (DIResaerch).
Nguva yekutumira: Kubvumbi-24-2024
.png)
